Skip to Content


In the US, Iopromide (iopromide systemic) is a member of the drug class non-ionic iodinated contrast media and is used to treat Cerebral Arteriography, Computed Tomography, Coronary Arteriography, Intra-arterial Digital Subtraction Angiography, Left Ventriculography, Peripheral Arteriography, Urography and Venography.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Iodinated x-ray contrast media

Chemical Name

1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(metoxyacetyl)amino]-N-metyl-

Foreign Names

  • Iopromidum (Latin)
  • Iopromid (German)
  • Iopromide (French)
  • Iopromida (Spanish)

Generic Names

  • Iopromide (OS: BAN, USAN, DCF, JAN)
  • ZK 35760 (Schering) (IS)
  • Iopromid (PH: Ph. Eur. 9)
  • Iopromide (PH: BP 2018, Ph. Eur. 9, USP 41)
  • Iopromidum (PH: Ph. Eur. 9)

Brand Names

  • Iopromide
    Fujifilm RI, Japan
  • Proscope
    Alfresa Pharma, Japan
  • Ravistu
    Kocsel, Turkey
  • Ultragraf-300
    Jenapharm, Germany
  • Ultragraf-370
    Jenapharm, Germany
  • Ultravist
    Adeofarma, Lithuania; Bayer, Brazil; Bayer, Canada; Bayer, Denmark; Bayer, Ecuador; Bayer, Estonia; Bayer, Georgia; Bayer, Greece; Bayer, Croatia (Hrvatska); Bayer, Ireland; Bayer, Italy; Bayer, Latvia; Bayer, Netherlands; Bayer, Norway; Bayer, Poland; Bayer, Sweden; Bayer, Slovenia; Bayer, Slovakia; Bayer, Turkey; Bayer Australia, Australia; Bayer Healthcare, Myanmar; Bayer Healthcare, United States; Bayer Hispania, Spain; Bayer Pharma, Macedonia; Bayer Pharma, Romania; Bayer Pharmaceuticals, Kuwait; Bayer Santé, France; Bayer Schering, Bulgaria; Bayer Schering, China; Bayer Schering, Lithuania; Bayer Schering, Tunisia; Bayer Schering Pharma, Russian Federation; BerliMed, Bulgaria; Lex ano, Lithuania; Schering, Oman; Scherring, Egypt; Zydus, India
  • Ultravist 150
    Bayer Vital, Germany
  • Ultravist 150mg
    Bayer Schweiz, Switzerland
  • Ultravist 240
    Bayer, Belgium; Bayer, Luxembourg; Bayer, New Zealand; Bayer Vital, Germany
  • Ultravist 240mg
    Bayer Schweiz, Switzerland
  • Ultravist 300
    Bayer, Belgium; Bayer, Luxembourg; Bayer, New Zealand; Bayer, Uruguay; Bayer Israel Ltd, Israel; Bayer Pharma, Serbia; Bayer Vital, Germany
  • Ultravist 300 mg I/ml
    Bayer, Hungary
  • Ultravist 300 mg J/ml
    Bayer Austria, Austria
  • Ultravist 300mg
    Bayer Schweiz, Switzerland
  • Ultravist 370
    Bayer, Belgium; Bayer, Luxembourg; Bayer, New Zealand; Bayer, Uruguay; Bayer Israel Ltd, Israel; Bayer Pharma, Serbia; Bayer Vital, Germany
  • Ultravist 370 mg I/ml
    Bayer, Hungary
  • Ultravist 370 mg J/ml
    Bayer Austria, Austria
  • Ultravist 370mg
    Bayer Schweiz, Switzerland
  • Ultravist 62.34%
    Bayer Hellas Abee, Cyprus
  • Ultravist 76.9%
    Bayer Hellas Abee, Cyprus
  • Ultravist-240
    Schering, Lithuania


BANBritish Approved Name
DCFDénomination Commune Française
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.